BRPI1007018B8 - composto ligante de receptores de adenosina, composição farmacêutica, e, uso de um composto. - Google Patents
composto ligante de receptores de adenosina, composição farmacêutica, e, uso de um composto.Info
- Publication number
- BRPI1007018B8 BRPI1007018B8 BRPI1007018A BRPI1007018A BRPI1007018B8 BR PI1007018 B8 BRPI1007018 B8 BR PI1007018B8 BR PI1007018 A BRPI1007018 A BR PI1007018A BR PI1007018 A BRPI1007018 A BR PI1007018A BR PI1007018 B8 BRPI1007018 B8 BR PI1007018B8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- adenosine
- pharmaceutical composition
- receptors
- receptor binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
composto, composição farmacêutica, e, uso de um composto. a presente invenção fornece novos compostos com alta afinidade por receptores a2a de adenosina. também fornece antagonistas de receptores a2a de adenosina e seu uso como medicamentos para o tratamento e/ou profilaxia de doenças e distúrbios onde a inativação parcial ou total de caminhos de sinalização de receptores a2a de adenosinas devem ser benéficos tal como mal de alzheimer, mal de parkinson, déficit de atenção e distúrbios de hiperatividade (adhd), doença de huntington, neuroproteção, esquizofrenia, ansiedade e dor. a presente invenção ainda diz respeito às composições farmacêuticas contendo tais novos compostos com alta afinidade por receptores a2a de adenosina e seu uso para o tratamento e/ou profilaxia de doenças e distúrbios onde a inativação parcial ou tal de receptores a2a de adenosina deve ser benéfica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09360007.0 | 2009-01-26 | ||
EP20090360007 EP2210891A1 (en) | 2009-01-26 | 2009-01-26 | New adenosine receptor ligands and uses thereof |
PCT/IB2010/000416 WO2010084425A1 (en) | 2009-01-26 | 2010-01-25 | New adenosine receptor ligands and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI1007018A2 BRPI1007018A2 (pt) | 2016-03-29 |
BRPI1007018B1 BRPI1007018B1 (pt) | 2020-03-10 |
BRPI1007018B8 true BRPI1007018B8 (pt) | 2021-05-25 |
Family
ID=40669959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1007018A BRPI1007018B8 (pt) | 2009-01-26 | 2010-01-25 | composto ligante de receptores de adenosina, composição farmacêutica, e, uso de um composto. |
Country Status (16)
Country | Link |
---|---|
US (1) | US9029393B2 (pt) |
EP (2) | EP2210891A1 (pt) |
JP (2) | JP5680553B2 (pt) |
CN (1) | CN102365280B (pt) |
AU (1) | AU2010207494B2 (pt) |
BR (1) | BRPI1007018B8 (pt) |
CA (1) | CA2750449C (pt) |
CY (1) | CY1114329T1 (pt) |
DK (1) | DK2391625T3 (pt) |
ES (1) | ES2419280T3 (pt) |
HK (1) | HK1167392A1 (pt) |
IL (1) | IL214167A (pt) |
NZ (1) | NZ594405A (pt) |
PT (1) | PT2391625E (pt) |
WO (1) | WO2010084425A1 (pt) |
ZA (1) | ZA201105791B (pt) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8221321B2 (en) | 2002-06-07 | 2012-07-17 | Verathon Inc. | Systems and methods for quantification and classification of fluids in human cavities in ultrasound images |
EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
US20120220581A1 (en) | 2009-10-30 | 2012-08-30 | Janssen-Cilag, S.A. | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
KR102008946B1 (ko) * | 2010-08-03 | 2019-08-08 | 노브알리스 도이칠란트 게엠베하 | 친화성 크로마토그래피에 의한 항체 및 Fc-융합 단백질 정제용 리간드 |
GB2497476B (en) * | 2010-09-06 | 2018-01-10 | Guangzhou Inst Biomed & Health | Amide Compounds |
WO2013000924A1 (en) | 2011-06-27 | 2013-01-03 | Janssen Pharmaceutica Nv | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
WO2013033620A1 (en) * | 2011-09-01 | 2013-03-07 | Irm Llc | Compounds and compositions as pdgfr kinase inhibitors |
KR20150013435A (ko) | 2012-02-08 | 2015-02-05 | 그라피니티 파머수티컬스 게엠베하 | 친화 크로마토그래피 IV에 의한 항체 및 Fc-융합 단백질 정제용 리간드 |
RU2657540C2 (ru) | 2012-06-26 | 2018-06-14 | Янссен Фармацевтика Нв | Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств |
CA2875057C (en) | 2012-07-09 | 2021-07-13 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyrazine compounds and their use as inhibitors of the phosphodiesterase 10 enzyme |
WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
JO3544B1 (ar) * | 2015-03-19 | 2020-07-05 | Kyowa Kirin Co Ltd | عامل علاجي للاختلال الوظيفي في الفص الجبهي |
KR20190078646A (ko) | 2016-11-18 | 2019-07-04 | 머크 샤프 앤드 돔 코포레이션 | 디아실글리세리드 o-아실트랜스퍼라제 2의 억제제로서 유용한 인다졸 유도체 |
EP3618829B1 (en) * | 2017-05-05 | 2023-06-07 | Arcus Biosciences, Inc. | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
CR20190593A (es) | 2017-06-22 | 2020-05-10 | Novartis Ag | Moléculas de anticuerpo que se unen a cd73 y usos de las mismas |
JP2021503478A (ja) | 2017-11-16 | 2021-02-12 | ノバルティス アーゲー | 組み合わせ治療 |
JP2021509009A (ja) | 2017-11-30 | 2021-03-18 | ノバルティス アーゲー | Bcmaターゲティングキメラ抗原受容体及びその使用 |
TW202400599A (zh) | 2018-02-27 | 2024-01-01 | 美商英塞特公司 | 作為a2a / a2b抑制劑之咪唑并嘧啶及***并嘧啶 |
IL301295A (en) | 2018-03-14 | 2023-05-01 | Surface Oncology Inc | Antibodies that bind CD39 and uses thereof |
CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
CR20200571A (es) | 2018-06-01 | 2021-01-18 | Novartis Ag | Moléculas de únion contra bcma y usos de las mismas |
TWI748194B (zh) * | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Fxr有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
TW202402759A (zh) | 2018-07-05 | 2024-01-16 | 美商英塞特公司 | 作為a2a/a2b抑制劑之稠合吡嗪衍生物 |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
CA3117512A1 (en) | 2018-10-25 | 2020-04-30 | Merck Patent Gmbh | 5-azaindazole derivatives as adenosine receptor antagonists |
JP7473544B2 (ja) | 2018-10-25 | 2024-04-23 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | アデノシン受容体アンタゴニストとしての5-アザインダゾール誘導体 |
WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶 |
JP2022524290A (ja) * | 2019-01-31 | 2022-05-02 | 杏林製薬株式会社 | 15-pgdh阻害薬 |
EP3921319B1 (en) * | 2019-02-07 | 2024-03-06 | BeiGene, Ltd. | Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist |
WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CA3124935A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2021055329A1 (en) | 2019-09-16 | 2021-03-25 | Surface Oncology, Inc. | Anti-cd39 antibody compositions and methods |
EP4031578A1 (en) | 2019-09-18 | 2022-07-27 | Novartis AG | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與entpd2抗體之組合療法 |
US20210115127A1 (en) | 2019-09-25 | 2021-04-22 | Surface Oncology, Inc. | Anti-il-27 antibodies and uses thereof |
US20230056470A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | 3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン |
CN116134027A (zh) | 2020-08-03 | 2023-05-16 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
EP4255904A2 (en) * | 2020-12-03 | 2023-10-11 | Domain Therapeutics | Novel par-2 inhibitors |
GB202019622D0 (en) * | 2020-12-11 | 2021-01-27 | Adorx Therapeutics Ltd | Antagonist compounds |
JP2024505049A (ja) | 2021-01-29 | 2024-02-02 | ノバルティス アーゲー | 抗cd73及び抗entpd2抗体のための投与方式並びにその使用 |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
CN115093372B (zh) * | 2022-06-16 | 2023-05-30 | 安徽工程大学 | 一种咪唑衍生物的合成方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2764387B1 (fr) | 1997-06-05 | 1999-07-23 | Centre Nat Rech Scient | Utilisation d'une proteine fluorescente pour la detection d'interactions entre une proteine cible et son ligand |
US7105550B2 (en) * | 2000-03-01 | 2006-09-12 | Christopher Love | 2,4-disubstituted thiazolyl derivatives |
JP2005530788A (ja) * | 2002-05-13 | 2005-10-13 | メルク エンド カムパニー インコーポレーテッド | フェニル置換イミダゾピリジン類およびフェニル置換ベンズイミダゾール類 |
US7186832B2 (en) * | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
EP1673085B1 (en) * | 2003-09-26 | 2011-11-09 | Exelixis, Inc. | C-met modulators and methods of use |
JP2005126374A (ja) * | 2003-10-24 | 2005-05-19 | Kissei Pharmaceut Co Ltd | 新規なアデノシンa2a受容体拮抗剤 |
TW200524887A (en) * | 2003-10-27 | 2005-08-01 | Lundbeck & Co As H | N-thiazol-2-yl-benzamide derivatives |
WO2006068954A2 (en) * | 2004-12-21 | 2006-06-29 | Schering Corporation | PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS |
WO2006107784A1 (en) * | 2005-04-05 | 2006-10-12 | Eli Lilly And Company | Imidazopyridazine compounds |
US7754717B2 (en) * | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
DE102005042742A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
WO2009060197A1 (en) * | 2007-11-08 | 2009-05-14 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazopyridazines for use as protein kinase inhibitors |
EP2240488B1 (en) * | 2008-02-06 | 2016-11-02 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
CA2755768A1 (en) * | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
WO2013033620A1 (en) * | 2011-09-01 | 2013-03-07 | Irm Llc | Compounds and compositions as pdgfr kinase inhibitors |
EP2822559B1 (en) * | 2012-03-09 | 2018-05-02 | Lexicon Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof |
-
2009
- 2009-01-26 EP EP20090360007 patent/EP2210891A1/en not_active Withdrawn
-
2010
- 2010-01-25 PT PT107083735T patent/PT2391625E/pt unknown
- 2010-01-25 CN CN201080013843.5A patent/CN102365280B/zh active Active
- 2010-01-25 EP EP20100708373 patent/EP2391625B1/en active Active
- 2010-01-25 US US13/146,327 patent/US9029393B2/en active Active
- 2010-01-25 CA CA2750449A patent/CA2750449C/en active Active
- 2010-01-25 AU AU2010207494A patent/AU2010207494B2/en active Active
- 2010-01-25 BR BRPI1007018A patent/BRPI1007018B8/pt active IP Right Grant
- 2010-01-25 JP JP2011546998A patent/JP5680553B2/ja active Active
- 2010-01-25 WO PCT/IB2010/000416 patent/WO2010084425A1/en active Application Filing
- 2010-01-25 ES ES10708373T patent/ES2419280T3/es active Active
- 2010-01-25 DK DK10708373T patent/DK2391625T3/da active
- 2010-01-25 NZ NZ59440510A patent/NZ594405A/xx unknown
-
2011
- 2011-07-19 IL IL214167A patent/IL214167A/en active IP Right Grant
- 2011-08-05 ZA ZA2011/05791A patent/ZA201105791B/en unknown
-
2012
- 2012-08-16 HK HK12108064.0A patent/HK1167392A1/xx unknown
-
2013
- 2013-06-19 CY CY20131100498T patent/CY1114329T1/el unknown
-
2015
- 2015-01-06 JP JP2015000660A patent/JP6201098B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
HK1167392A1 (en) | 2012-11-30 |
EP2391625B1 (en) | 2013-05-01 |
ES2419280T3 (es) | 2013-08-20 |
BRPI1007018B1 (pt) | 2020-03-10 |
JP5680553B2 (ja) | 2015-03-04 |
US9029393B2 (en) | 2015-05-12 |
IL214167A (en) | 2017-09-28 |
BRPI1007018A2 (pt) | 2016-03-29 |
CY1114329T1 (el) | 2016-08-31 |
AU2010207494B2 (en) | 2015-12-03 |
NZ594405A (en) | 2013-09-27 |
IL214167A0 (en) | 2011-08-31 |
ZA201105791B (en) | 2014-01-29 |
WO2010084425A1 (en) | 2010-07-29 |
CN102365280B (zh) | 2014-10-29 |
DK2391625T3 (da) | 2013-07-01 |
CA2750449A1 (en) | 2010-07-29 |
JP2012515759A (ja) | 2012-07-12 |
CN102365280A (zh) | 2012-02-29 |
EP2391625A1 (en) | 2011-12-07 |
US20110288074A1 (en) | 2011-11-24 |
JP2015110599A (ja) | 2015-06-18 |
PT2391625E (pt) | 2013-07-05 |
EP2210891A1 (en) | 2010-07-28 |
JP6201098B2 (ja) | 2017-09-27 |
CA2750449C (en) | 2018-03-13 |
AU2010207494A1 (en) | 2011-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1007018B8 (pt) | composto ligante de receptores de adenosina, composição farmacêutica, e, uso de um composto. | |
MA32898B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone | |
HN2010002030A (es) | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 | |
CR10309A (es) | "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1" | |
BR112013004766A2 (pt) | 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3 | |
HN2012001265A (es) | Modulares alostericos positivos de receptores mi1 de la quinolina amida | |
BRPI0919876A8 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo. | |
BR112012010253A2 (pt) | compostos de pirimidina como moduladores do receptor delta opioide | |
UY32923A (es) | Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico | |
BR112015015468B8 (pt) | Composto, e, composição farmacêutica | |
BR112013002250A2 (pt) | composto, medicamento, método para a profilaxia ou tratamento de depressão, esquisofrenia, mal de alzheimer ou distúrbio de hiperatividade e déficit de atenção, e, uso de um composto. | |
BR112014001908A2 (pt) | derivados aza heterocíclicos substituídos | |
BRPI0719092B8 (pt) | compostos do tipo tetra-hidrociclopen-ta[b]indol, seus usos, e composição farmacêutica | |
CL2012001673A1 (es) | Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras. | |
BRPI0508724A (pt) | derivados do fenilaminoetanol como agonistas do receptor beta2 | |
CL2011000137A1 (es) | Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis | |
BR112012003464B8 (pt) | compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica | |
BR112014024479A8 (pt) | Formulações farmacêuticas compreendendo antagonistas de c-cr3 | |
MA32943B1 (fr) | Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique | |
MX2009003645A (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3. | |
BR112015019802A2 (pt) | formulações farmacêuticas de nitrito e usos das mesmas | |
BR112013004721A2 (pt) | "quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3" | |
BR112018013955A2 (pt) | ligantes de dopamina d3 de 6,7,8,9-tetra-hidro-5h-pirido[2,3-d]azepina | |
BR112013004562A2 (pt) | 2-óxi-quinolina-3-carboxamidas substituídas como moduladores kcnq2/3 | |
CL2009000445A1 (es) | Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: KALDI PHARMA (FR) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/03/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/01/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |